Immunological and clinical analysis of tumor antigen specific immunotherapy combined with chemotherapy against ovarian cancer
| Project/Area Number |
24791698
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
SUZUKI Shiro 名古屋大学, 医学部附属病院, 助教 (20612758)
|
|---|
| Research Collaborator |
中面 哲也 国立がん研究センター 先端医療開発センター, 医薬品開発グループ, 免疫療法開発分野長(柏)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 悪性卵巣腫瘍 / 腫瘍免疫 / 婦人科腫瘍 |
|---|
| Outline of Final Research Achievements |
To evaluate the efficacy of glypican-3 (GPC3) peptide vaccine therapy combined with chemotherapy, ovarian clear cell carcinoma (OCCC) patients with residual tumor after initial treatment were enrolled in our clinical trial. Seven OCCC patients were received GPC3-derived peptide vaccine combined with chemotherapy.
Immunological responses were analyzed by ex vivo IFN-γ enzyme-linked immunospot assay. In three out of four evaluable patients, the frequency of GPC3 peptide-specific CTLs after vaccination was slightly larger than that before vaccination. Concurrent standard-dose chemotherapy may impair GPC3 peptide vaccine-induced immunity.
Moreover, we established several HLA-A24-restricted GPC3 peptide-specific CTL clones from peripheral blood mononuclear cells of two out of nine patients vaccinated with GPC3 peptide by single cell sorting using Dextramer antibody.
|
Report
(4 results)
Research Products
(27 results)
-
-
[Journal Article] Oncologic Outcome after Recurrence in Patients with Stage I Epithelial Ovarian Cancer: ~Are Clear-cell and Mucinous Histological Types a Different Entities?2014
Author(s)
Kajiyama H, Mizuno M, Shibata K, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Sekiya, R, Niimi K, Kawai M, Nagasaka T, Kikkawa F.
-
Journal Title
Eur J Obstet Gynecol Reprod Biol.
Volume: 181
Pages: 305-10
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Is there any association between where patients spend the end of life and survival after anticancer treatment for gynecologic malignancy?2014
Author(s)
Kajiyama H, Utsumi F, Higashi M, Sakata J, Sekiya R, Mizuno M, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Niimi K, Shibata K, Kikkawa F.
-
Journal Title
J Palliat Med.
Volume: 17
Issue: 3
Pages: 325-30
DOI
Related Report
Peer Reviewed
-
[Journal Article] Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology.2014
Author(s)
Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Sekiya R, Niimi K, Mitsui H, Yamamoto E, Kawai M, Nagasaka T, Kikkawa F.
-
Journal Title
J Gynecol Oncol.
Volume: 25
Issue: 1
Pages: 43-50
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy．2013
Author(s)
Nobuoka D, Yoshikawa T, Takahashi M, Iwama T, Horie K, Shimomura M, Suzuki S, Sakemura N, Nakatsugawa M, Sadamori H, Yagi T, Fujiwara T, Nakatsura T
-
Journal Title
Cancer Immunol Immunother
Volume: 62(4)
Issue: 4
Pages: 639-652
DOI
NAID
Related Report
Peer Reviewed
-
[Journal Article] The expression and characterization of endoglin in uterine leiomyosarcoma.2013
Author(s)
Mitsui H, Shibata K, Mano Y, Suzuki S, Umezu T, Mizuno M, Yamamoto E, Kajiyama H, Kotani T, Senga T, Kikkawa F.
-
Journal Title
Clin Exp Metastasis.
Volume: Epub ahead of print
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
